Study to Evaluate the Efficacy and Safety of Finerenone on Morbidity & Mortality in Participants With Heart Failure with Preserved Ejection Fraction (HFpEF) (FINEARTS-HF)

In by ECIR

Locations
St. Augustine
Condition
Heart Failure

Study to Evaluate the Efficacy and Safety of Finerenone on Morbidity & Mortality in Participants With Heart Failure with Preserved Ejection Fraction (HFpEF) (FINEARTS-HF)

  • Hidden
  • This field is for validation purposes and should be left unchanged.
clinicaltrials.gov

Eligibility

Inclusion Criteria
  1. Male or Female ≥ 40 years of age
  2. LVEF ≥ 40% & HF NYHA Class II-IV
  3. NT-proBNP ≥ 300 in NSR or NT-proBNP ≥ 900 in AFib
  4. Treated with diuretics within 30 days
  5. Structural heart abnormalities confirmed via ECHO (LAD ≥ 3.8 cm, LAA ≥ 20 cm2, LACI ≥ 115 g/m2, septal thickness or posterior wall thickness ≥ 1.1 cm)
Exclusion Criteria
  1. GFR <25 ml/min
  2. K levels > 5 mmol/L
  3. MI, stroke, or TIA within 90 days
  4. PCI, or CABG within 90 days
  5. Severe pulmonary disease
  6. BMI > 50 kg/m2
Back to Current Studies